Neulasta 6 mg solution for injection
Sponsors
Karolinska University Hospital, Celgene Corp., Sutro Biopharma Inc., IRCCS Istituto Giannina Gaslini, AstraZeneca AB
Conditions
Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)High-risk Large B-cell LymphomaLarge B-cell LymphomaNon-metastatic HER2-positive Breast CancerSevere chronic neutropenia (SCN)
Phase 2
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE
RecruitingCTIS2022-501504-95-00
Start: 2023-06-23Target: 402Updated: 2025-08-18
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice (IC) Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)
CompletedCTIS2024-512477-27-00
End: 2025-03-28Target: 193Updated: 2025-04-18
Use of pegfilgrastim in severe chronic neutropenia
Not yet recruitingCTIS2024-519009-36-01
Target: 20Updated: 2025-01-31
Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma
(GOLSEEK-1)
Active, not recruitingCTIS2023-510178-15-00
Start: 2024-07-31Target: 322Updated: 2025-09-10
A Phase III, Multicentre, Open-Label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP x2 followed by AZD0486 versus R-mini-CHOP x6 in Elderly or Unfit Participants with Newly Diagnosed Large B-cell Lymphoma (SOUNDTRACK-D2)
Not yet recruitingCTIS2025-522029-37-00
Target: 14Updated: 2026-01-30